Inovio Pharmaceuticals

INO · NASDAQ

$1.01+$0.01 (+1.00%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $1.00

About INO

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 112 full-time employees. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

Employees: 112
Headquarters: Plymouth Meeting, Pennsylvania
Listed: Dec 8, 1998
Sector: Health Care
Industry: Biotechnology
Website: inovio.com

Leadership

Inovio Pharmaceuticals executives
Name	Title	Since	Age
Simon Benito	—	—	80
Jacqueline Shea	—	2019	59
Jay Shepard	—	—	67
Peter Kies	—	—	61
Laurent Humeau	—	—	58
Michael Sumner	—	—	60
David Weiner	—	—	69
Roger Dansey	—	—	69
Ann Miller	—	—	67
Wendy Yarno	—	—	70
Lota Zoth	—	—	65

Revenue by product and region

Fiscal year ended Dec 31, 2021: $1.77M total revenue

By product

Revenue under collaborative research and development arrangements$902.26K50.8%
Other revenue$627.19K35.3%
Revenue under collaborative research and development arrangements from affiliated entities$245.31K13.8%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Inovio Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
OncoSec Medical ONCS	Supplier and customer	US	0.88
QIAGEN QGEN	Supplier and customer	NL	0.62
Regeneron Pharmaceuticals REGN	Supplier	US	-0.46
AstraZeneca AZN.L	Supplier and customer	GB	-0.67
United States	Customer	US	—
Plumbline Life Sciences	Supplier and customer	KR	—
Geneos Therapeutics, Inc.	Supplier and customer	US	—
Cancer Research Institute	Supplier and customer	US	—
Parker Institute For Cancer Immunotherapy	Supplier and customer	US	—
University Hospitals Geneva Medical Center	Supplier and customer	US	—

Similar companies

Companies in the same industry as Inovio Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.